<DOC>
	<DOCNO>NCT01093794</DOCNO>
	<brief_summary>This study test hypothesis Final Market Image ( FMI ) sitagliptin/metformin 50 mg/500 mg 50 mg/850 mg ( Fixed Dose Combination ) FDC tablet co-administration corresponding dose sitagliptin China-sourced metformin individual tablet bioequivalent base assessment AUC ( 0-t ) Cmax , sitagliptin metformin .</brief_summary>
	<brief_title>Bioequivalence Study Sitagliptin/Metformin Combination Tablet ( MK0431A-122 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subject Chinese descent Subject good health Subject nonsmoker Subject history stroke chronic seizure Subject history cancer Subject major surgery , donate blood participate another investigational study within past 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>